Skip to main content
OpenTrials
Completed

NCT Number: NCT00867412

Randomized Study of Positron Emission Tomography - Computed Tomography (PET/CT) in Pre-Operative Staging of Lung Cancer

Patients with possible operable non-small cell lung cancer are randomised to conventional staging, or conventional staging and PET/CT. According to, patients with operable tumor will be referred to surgery, and the number of thoracotomies and futile thoracotomies wil be compared with the two groups in order to asses the possible benefit of PET/CT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

PET & Cyclotron Unit, Rigshospitalet,

Copenhagen, 2100, Denmark

About this study

Patients with possible operable NSCLC after staging with CT are randomised to PET-CT with FDG or not, prior to mediastinoscopy. All patients are referred to mediastinoscopy unless a positive FDG uptake results in a positive biopsy suggesting stage IV disease.

Biopsies are performed according to the following criteria:

  • Lymph nodes are numbered according the Mountain classification, and abnormal lesions must be confirmed histologically, by mediastinoscopy or thoracotomy.
  • PET-positive lesions in the liver must be biopsied unless ultrasound or MRI unequivocally indicate the lesions are benign cysts or haemangioma.
  • PET-negative adrenal lesions are accepted without biopsy if CT scan indicate the lesion is a benign adenoma.
  • PET-positive bone lesions must be evaluated by plain x-ray, CT, MRI, or bone scintigraphy. In case of equivocal findings a biopsy must be performed.
  • PET-positive brain lesions must be confirmed by CT or MRI.

Number of patients:

Patients with clinically operable NSCLC after CT-staging are included. All patients must have mediastinoscopy performed.

All patients referred to mediastinoscopy can be randomised after informed consent. A total of 430 consecutive, non-selected patients are planned. It is anticipated that approximately 60% of the referred patients with clinical stage I-IIIa NSCLC will undergo thoracotomy, and a risk of type I and II error of 5% and 10%, respectively, is accepted. Thus a total of 215 patients are randomised in each arm in order to observe an absolute difference of 15% in the number of thoracotomies. This number seems to be sufficient to evaluate differences in the secondary endpoints.

After inclusion of a total of 220 patients, corresponding to 110 PET-scans, an interim analyses are performed. In case of a highly significant difference in the number of thoracotomies (p < 0,001) the study will be closed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically operable NSCLC after CT
  • Fit for thoracotomy and lobectomy or pneumectomy after lung function tests
  • CT-scan of thorax, including liver and adrenals with no signs of distant metastases.
  • No medical condition contraindication surgery.
  • Age 18-80
  • No claustrophobia.
  • Negative pregnancy test.
  • No diabetes mellitus.
  • Signed informed consent.

Exclusion criteria

  • Radiologically M1 disease.
  • Pregnancy
  • Known claustrophobia.
  • Estimated FEV1 < 30% of expected after surgery.
  • Diabetes mellitus.

Treatment and study plan

Primary outcomes

  1. Number of futile thoracotomies

    Time frame: Within 1 year

Secondary outcomes

  1. Number of thoracotomies and survival

    Time frame: Within 1 year

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Danish Cancer Society
  • Danish Centre for Health Technology Assessment

Registry information

Official study title

Randomized Study of PET/CT in Pre-Operative Staging of Lung Cancer

Important dates

Study start
2002
Primary completion
2007
Study completion
2008
First posted
Mar 23, 2009
Registry last updated
Mar 23, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.